Aldeyra Therapeutics Inc ALDX

Overview

Aldeyra Therapeutics, Inc. is a biotechnology company dedicated to the development and commercialization of advanced therapies aimed at treating immune-mediated diseases. Founded in 2004 and undergoing a name change from Aldexa Therapeutics, Inc. to Aldeyra Therapeutics, Inc. in March 2014, the company is headquartered in Lexington, Massachusetts. By focusing on innovative treatments, Aldeyra seeks to address the underserved needs within various patient populations affected by these challenging conditions.

Products and Services

• Reproxalap: This is Aldeyra's lead product candidate, a novel reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials aimed at treating dry eye diseases. It represents the forefront of the company's R&D, targeting a common yet often inadequately addressed condition.
• ADX-629: An orally administered RASP modulator intended for a broad range of conditions, including COVID-19, atopic asthma, psoriasis, and alcohol intoxication. By modulating RASP, ADX-629 aims to deliver therapeutic benefits across these diverse conditions, highlighting the versatility of Aldeyra's technology platform.
• ADX-2191: Developed as a dihydrofolate reductase inhibitor, ADX-2191 targets the treatment of retinitis pigmentosa, alongside other rare retinal diseases characterized by inflammation and vision loss. This underscores Aldeyra's commitment to addressing rare and serious eye diseases with significant unmet medical needs.
• ADX-246 and ADX-248: These compounds are in development for systemic immune-mediated diseases and geographic atrophy, respectively. Although details are less specified, these projects exemplify Aldeyra's broadened focus into a wider array of immune-related disorders and its continuous pursuit of innovation in the biotechnology sector.